
Annual report 2024
added 02-21-2026
Midatech Pharma plc Net Debt 2011-2026 | MTP
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Midatech Pharma plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -6.17 M | -1.63 M | -7.05 M | -15.5 M | -14.4 M | -28.4 M | -1.24 M | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.24 M | -28.4 M | -10.6 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
-47.4 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Cabaletta Bio
CABA
|
-188 M | $ 3.34 | 0.45 % | $ 3.9 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Codexis
CDXS
|
12.5 M | $ 1.02 | 1.49 % | $ 74.9 M | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Cerus Corporation
CERS
|
-6.33 M | $ 2.6 | 1.37 % | $ 480 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 3.87 | -0.39 % | $ 116 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
CNS Pharmaceuticals
CNSP
|
-13.6 M | $ 3.23 | 2.22 % | $ 1.23 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Collegium Pharmaceutical
COLL
|
-226 M | $ 41.75 | 0.19 % | $ 1.32 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
-114 M | $ 36.14 | 1.23 % | $ 3.75 B | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Amarin Corporation plc
AMRN
|
-189 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
-706 M | $ 23.77 | 2.99 % | $ 2.91 B | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
263 K | $ 8.41 | -1.87 % | $ 36.4 M | ||
|
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.94 | 0.01 % | $ 130 M | ||
|
Curis
CRIS
|
-17 M | $ 1.1 | -3.51 % | $ 6.94 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
CorMedix
CRMD
|
-43 M | $ 7.16 | 0.42 % | $ 364 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Champions Oncology
CSBR
|
-8.23 M | $ 6.14 | 3.89 % | $ 83.9 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Citius Pharmaceuticals
CTXR
|
-2.99 M | $ 0.72 | -2.34 % | $ 4.84 M | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
Altimmune
ALT
|
-35.2 M | $ 4.21 | -2.32 % | $ 299 M | ||
|
CEL-SCI Corporation
CVM
|
3.45 M | $ 3.88 | -8.92 % | $ 247 M |